Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Kowalewski

Showing results (141-150 of 167) with videos related to

Pageof 17
Sort By:
Journal of Proteome Research|May 17, 2019
Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer ImmunotherapyJ Patrick Murphy, Youra Kim, Derek R Clements, et al.
Journal of Proteome Research|March 1, 2017
MHC-I Ligand Discovery Using Targeted Database Searches of Mass Spectrometry Data: Implications for T-Cell ImmunotherapiesJ Patrick Murphy, Prathyusha Konda, Daniel J Kowalewski, et al.
Leukemia|August 6, 2014
Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapyC Berlin, D J Kowalewski, H Schuster, et al.
Leukemia|April 7, 2016
Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapyC Berlin, D J Kowalewski, H Schuster, et al.
Blood Cancer Journal|April 9, 2016
Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-terminiD J Kowalewski, S Walz, L Backert, et al.
Oncoimmunology|April 11, 2018
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapyAnnika Nelde, Daniel J Kowalewski, Linus Backert, et al.
The Journal of Experimental Medicine|August 18, 2018
Identification of non-mutated neoantigens presented by TAP-deficient tumorsKoen A Marijt, Laura Blijleven, Els M E Verdegaal, et al.
Plos One|November 29, 2016
Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell ImmunotherapySharon M Barth, Christian M Schreitmüller, Franziska Proehl, et al.
Analytical Chemistry|February 20, 2019
Multiplexed Relative Quantitation with Isobaric Tagging Mass Spectrometry Reveals Class I Major Histocompatibility Complex Ligand Dynamics in Response to DoxorubicinJ Patrick Murphy, Qijia Yu, Prathyusha Konda, et al.
Proteomics|March 6, 2018
Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target SelectionJens Fritsche, Barbara Rakitsch, Franziska Hoffgaard, et al.
Pageof 17

Showing results (141-150 of 167) with videos related to

Sort By:
Pageof 17
Journal of Proteome Research|May 17, 2019
Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer ImmunotherapyJ Patrick Murphy, Youra Kim, Derek R Clements, et al.
Journal of Proteome Research|March 1, 2017
MHC-I Ligand Discovery Using Targeted Database Searches of Mass Spectrometry Data: Implications for T-Cell ImmunotherapiesJ Patrick Murphy, Prathyusha Konda, Daniel J Kowalewski, et al.
Leukemia|August 6, 2014
Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapyC Berlin, D J Kowalewski, H Schuster, et al.
Leukemia|April 7, 2016
Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapyC Berlin, D J Kowalewski, H Schuster, et al.
Blood Cancer Journal|April 9, 2016
Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-terminiD J Kowalewski, S Walz, L Backert, et al.
Oncoimmunology|April 11, 2018
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapyAnnika Nelde, Daniel J Kowalewski, Linus Backert, et al.
The Journal of Experimental Medicine|August 18, 2018
Identification of non-mutated neoantigens presented by TAP-deficient tumorsKoen A Marijt, Laura Blijleven, Els M E Verdegaal, et al.
Plos One|November 29, 2016
Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell ImmunotherapySharon M Barth, Christian M Schreitmüller, Franziska Proehl, et al.
Analytical Chemistry|February 20, 2019
Multiplexed Relative Quantitation with Isobaric Tagging Mass Spectrometry Reveals Class I Major Histocompatibility Complex Ligand Dynamics in Response to DoxorubicinJ Patrick Murphy, Qijia Yu, Prathyusha Konda, et al.
Proteomics|March 6, 2018
Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target SelectionJens Fritsche, Barbara Rakitsch, Franziska Hoffgaard, et al.
Pageof 17